Valeo Pharma Inc VPHIF

VPH....in final stage of clinical trials in Canada

[oiljack14]

VPH....in final stage of clinical trials in Canada for a Covid-19 drug treatment for respiratory issues related to Covid 19. Part of WHO sponsored world wide study! https://stockhouse.com/opinion/independent-reports/2020/05/22/valeo-pharma-bringing-to-market-drug-undergoing-clinical-trials-to-improve Some of the respiratory failures COVID-19 patients suffer from are due to small blood vessel thrombosis – small clots in different organs including the lungs – where you can't get enough oxygen into the body because some of the blood vessels that come out of the lungs are clotted off. It has been shown that heparin actually interferes with the virus's ability to bind to surfaces in the body, and heparin may have a specific anti-viral effect. A large-scale clinical trial testing the blood thinner heparin was launched around the world this mid-May 2020, led by a team of clinician-scientists from the University of Manitoba in Canada and the University Health Network. The World Health Organization has as one of its guidelines for COVID-19 patient treatment the use of low molecular weight heparin to prevent complications resulting from the virus infection. There are ongoing studies evaluating whether the use of low molecular weight heparin could also increase recovery time and decrease overall mortality related to COVID-19; e.g. the Italian Medicines Agency (AIFA) has given the green light to a new clinical study to reduce mortality from Covid-19: a group of patients will be administered the low molecular weight heparin anticoagulant in therapeutic doses. The evidence is building linking anticoagulation to COVID-19 Survival; among nearly 3000 patients with COVID-19 admitted to New York City's Mount Sinai Health System beginning in mid-March, median survival increased from 14 days to 21 days with the addition of anticoagulation low molecular weight heparin. https://clinicaltrials.gov/ct2/show/NCT04323761 - Canadian study being coordinated with other jurisdictions around the world. This IS the VPH drug. IF approved we have our home run. GS-US-540-5821 (Control # 238163) Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-COV2 (COV) Infection Treatment: remdesivir Gilead Sciences Canada Inc. 2020-04-15 NCT04323761 https://clinicaltrials.gov/ct2/show/NCT04397510 - United States FDA approved clinical study out of Maryland. This is the US name for the Valeo branded drug “Remdesivir” Brief Summary: Randomized, placebo controlled study to determine if nebulized heparin may reduce the severity of lung injury caused by the novel coronavirus, also known as COVID-19 Condition or disease Intervention/treatment Phase Covid-19ARDS, HumanAcute Lung Injury Drug: HeparinDrug: 0.9% Sodium-chloride Phase 4 Show detailed description Study Design Go to Study Type : Interventional (Clinical Trial) Estimated Enrollment : 50 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury Actual Study Start Date : June 1, 2020 Estimated Primary Completion Date : December 31, 2020 Estimated Study Completion Date : December 31, 2020